Full text is available at the source.
Abstract
Cagrilintide and its combination with semaglutide may offer new treatment options for obesity.
- Cagrilintide is a once-weekly amylin receptor agonist aimed at weight management.
- The fixed-dose combination of cagrilintide and semaglutide (CagriSema) is explored as a novel pharmacotherapy.
- This systematic review and meta-analysis assessed the efficacy and safety of these treatments in adults with overweight or obesity.
Simplified